{
  "docId": "019de076-567f-77cd-b2fe-46fe5b90ebce",
  "docSlug": "f071473f2318bf29da28de95df17ba43",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 27,
  "pageCount": 31,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Uses a chevron-based process flow to represent maturity stages.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-567f-77cd-b2fe-46fe5b90ebce/27",
  "deckHref": "/decks/019de076-567f-77cd-b2fe-46fe5b90ebce",
  "deckJsonHref": "/decks/019de076-567f-77cd-b2fe-46fe5b90ebce.json",
  "deckAnchorHref": "/decks/019de076-567f-77cd-b2fe-46fe5b90ebce#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.92,
        "x": 0.04,
        "y": 0.3
      },
      "kind": "diagram",
      "text": "PROVEN, UNDER EVALUATION, FUTURE",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97f50f8c-3f90-4637-b958-650e4abecccb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.35,
        "x": 0.58,
        "y": 0.35
      },
      "kind": "list",
      "text": "Potential Therapeutic Applications: INFECTION (Anti-infectives, Antivirals), INFLAMMATION (Autoimmune, Neuro-inflammatory, Acute/chronic), ONCOLOGY (Hematologic & solid tumor)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41cc9fbb-64ad-4d87-809a-2a0c14160feb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.31,
        "y": 0.5
      },
      "kind": "list",
      "text": "Intracellular Delivery of Nucleic Acids: siRNA, ASO",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7954755-7c2d-4c3c-8a7f-672e3dc0df3a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "list",
      "text": "Oral Formulations of Anti-Infectives: MAT2203, Remdesivir, MAT2501. Oral Formulations of Chemotherapeutics: Docetaxel",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fce0c220-3526-42fe-93b9-264379b5b264",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.1,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "Matinas is working internally and with third parties to broaden its pipeline of LNC-based therapeutics",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a1ace88-c1f9-457c-891b-ea470a2244dc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.32,
        "x": 0.34,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "* Key Areas of Focus for Internal LNC Oral Small Oligonucleotides",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a1a9e71-8151-48a3-99e3-ab2cf82bcba3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.5,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "Unlocking the Full Potential of the LNC Platform",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81997184-f69f-45f0-82f8-5ea543edf8c1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "ca6f3cdd-7927-4592-9294-1a073f4eedbf",
      "evidence": "The slide contains several list/bullet items, indicating a list presentation.",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "f5acfaa8-8c59-4a91-b785-7df3d79e0cef",
      "evidence": "Chevron-based progression from Proven to Future",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 29,
      "from": 27,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "d5dcfd9b-543a-4162-93c1-7a55c50880a6",
      "evidence": "Rapid Evolution of Platform Sets Stage for Active Q4 and Expanding LNC Intellectual Property Portfolio",
      "position": 1,
      "objective": "Explain why now is the right time for Matinas BioPharma",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.6,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}